Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 1987-04-08 | Forward | 3:1 |
OraSure Technologies develops and sells oral fluid diagnostic and specimen collection products globally, including COVID-19, HIV, HCV, Ebola tests, and genomic solutions for healthcare, research, and public health markets.
OraSure Technologies' OraQuick™ HIV Self-Test is the first FDA-approved, at-home oral fluid rapid test for HIV-1 and HIV-2 antibodies, delivering results in 20 minutes and expanding globally, including recent approval in Canada.
In December 2025, OraSure Technologies confirmed that activist investor Altai Capital notified the company of its intent to nominate two candidates to the Board of Directors at the 2026 Annual Meeting. This action put the company's corporate governance and strategic direction in the spotlight, signaling pressure from a significant shareholder for potential changes.
Establishment Labs (NASDAQ: ESTA - Get Free Report) and OraSure Technologies (NASDAQ: OSUR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations. Analyst Recommendations This is a summary of
Shares of OraSure Technologies, Inc. (NASDAQ: OSUR - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $3.68 and traded as high as $4.13. OraSure Technologies shares last traded at $3.77, with a volume of 534,071 shares trading hands. Analyst Ratings Changes OSUR has
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
 PRE | $22.14 | COMPARE |
 PROF | $6.68 | COMPARE |
 UTMD | $73.93 | COMPARE |
 NAUT | $1.76 | COMPARE |
 STIM | $2.13 | COMPARE |
 TARA | $2.63 | COMPARE |
 NYXH | $1.33 | COMPARE |
 NTHI | $2.56 | COMPARE |
